Hopp til innhold
NHI.no
Annonse

Leishmaniasis: Behandling

Behandlingen er krevende med medikamenter som i seg selv kan være belastende for kroppen. Ved visceral leishmaniasis er det nødvendig med innleggelse i sykehus.

Det foregår utprøving av vaksiner mot visceral leishmaniasis, men det er enda ikke funnet noen effektiv vaksine. 

Annonse

Dette dokumentet er basert på det profesjonelle dokumentet Leishmaniasis . Referanselisten for dette dokumentet vises nedenfor

  1. Markle WH, Makhoul K. Cutaneous Leishmaniasis: Recognition and treatment. Am Fam Physician 2004; 69: 455-60. PubMed
  2. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet 2005; 366: 1561-77. PubMed
  3. WHO: Leishmaniasis. Nettside besøkt 04.07.24. www.who.int
  4. World Health Organization. Fact sheet: leishmaniasis. Januar 2023. http://www.who.int/ (last accessed 08 Juli 2024).
  5. Burza S, Croft SL, Boelaert M. Leishmaniasis. Lancet 2018; 392: 951–70. PMID: 30126638 PubMed
  6. European Centre for Disease Prevention and Control: Phlebotomine sand flies - Factsheet for experts. Nettside sist oppdatert 15.06.20., nettsiden besøkt 04.07.24.
  7. Reithinger R, Chappuis F. Leishmaniasis. Best Practice BMJ, last updated Nov 2017. bestpractice.bmj.com
  8. Müller KE, Blomberg B, Tellevik MG, et al. Leishmaniasis i Norge. Tidsskr Nor Legeforen 2021. doi:10.4045/tidsskr.19.0171 DOI
  9. Hirve S, Kroeger A, Matlashewski G, et al. Towards elimination of visceral leishmaniasis in the Indian subcontinent-Translating research to practice to public health. PLoS Negl Trop Dis 2017; 11: e0005889. PMID: 29023446 PubMed
  10. Blomberg B, Müller KE, Helgeland L, et al. En mann i 80-årene med leddgikt og vedvarende feber. Tidsskr Nor Legeforen 2019. doi:10.4045/tidsskr.18.0546 DOI
  11. Belkaid Y, Mendez S, Lira R, Kadambi N, Milon G and Sacks D. A natural model of Leishmania major infection reveals a prolonged "silent" phase of parasite amplification in the skin before the onset of lesion formation and immunity. J Immunol 2000; 165: 969-77. PubMed
  12. Fletcher K, Issa R, Lockwood DN. Visceral leishmaniasis and immunocompromise as a risk factor for the development of visceral leishmaniasis: a changing pattern at the hospital for tropical diseases, london. PLoS One 2015; 10: e0121418. PMID: 25831056 PubMed
  13. Folkehelseinstituttet. Leishmaniasis - veileder for helsepersonell. Sist oppdatert 22.11.2022. www.https
  14. Aronson N, Herwaldt BL, Libman M, et al. Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis 2016; 63: e202–64. PMID: 27941151 PubMed
  15. Blum J, Buffet P, Visser L, et al. LeishMan recommendations for treatment of cutaneous and mucosal leishmaniasis in travelers, 2014. J Travel Med 2014; 21: 116–29. PMID: 24745041 PubMed
  16. Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ 2001; 323: 419-22. PubMed
  17. Salah AB, Messaoud NB, Guedri E, et al . Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. N Engl J Med 2013; 368: 524-32. New England Journal of Medicine
  18. Alvar J, Vélez ID, Bern C, et al; WHO Leishmaniasis Control Team. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7:e35671. PubMed
  19. Sundar S, Chakravarty J, Agarwal D, et al. Singe-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 2010; 362: 504-12. New England Journal of Medicine
  20. WHO: Status of endemicity of visceral leishmaniasis. Nettside sist oppdatert 29.09.23, nettsiden besøkt 04.07.24. www.who.int
Annonse
Annonse